Koji Hatano

ハタノコウジ | Koji Hatano

Affiliation and department：

Research field (1)： Urology

Research theme for competitive and other funds (16)：

2022 - 2027 前立腺特異的膜抗原(PSMA)を標的とした革新的α線治療薬の実用化に向けた医師主導治験の実施
2023 - 2026 腫瘍微小環境における多因子間相互作用ネットワーク定量的検出への挑戦
2023 - 2026 腸内細菌叢によるアンドロゲンシグナル経路を介した去勢抵抗性前立腺癌進展機序の解明
2022 - 2026 遺伝的素因、生活習慣、腸内細菌叢の多面的解析に基づく前立腺癌の早期診断戦略の構築
2022 - 2025 生活習慣による代謝物プロファイル変化を介する前立腺癌の増殖制御

Show all

Papers (171)：

Akihiro Yoshimura, Taigo Kato, Yasutomo Nakai, Masao Tsujihata, Shingo Toyoda, Mototaka Sato, Kyosuke Matsuzaki, Wataru Nakata, Tetsuya Takao, Syunsuke Inoguchi, et al. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan. International journal of clinical oncology. 2024
Chisato Wakamori, Marco A De Velasco, Kazuko Sakai, Yurie Kura, Makoto Matsushita, Saizo Fujimoto, Koji Hatano, Norio Nonomura, Kazutoshi Fujita, Kazuto Nishio, et al. A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk. The Prostate. 2024
Atsunari Kawashima, Yu Ishizuya, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano, Norio Nonomura. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution. International journal of clinical oncology. 2024. 29. 8. 1096-1104
Kohei Segawa, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano, Yoichi Kakuta, Atsunari Kawashima, Shinichiro Fukuhara, Norio Nonomura. A case of malignant pheochromocytoma with neurofibromatosis type 1 having difficulty in differentiating spinal tumor. IJU case reports. 2024. 7. 4. 336-340
Masaru Tani, Koji Hatano, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Toshiki Oka, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, et al. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management. Scientific reports. 2024. 14. 1. 13451-13451

ｍore...

MISC (258)：

サシネスリン, 河嶋厚成, 山本顕生, 木村友則, 三田真史, 山本致之, 石津谷祐, 加藤大悟, 波多野浩士, 野々村祝夫. D-Amino acids, promotes Urothelial cancer cell proliferation, invasion and migration. 泌尿器科分子・細胞研究会プログラム・抄録集. 2024. 33rd
河嶋厚成, 山本顕生, ネスリンサッシ, 木村友則, 三田真史, 神宮司健太郎, 植村俊彦, 山道岳, 冨山栄輔, 石津谷祐, et al. Diagnostic and prognostic markers using bacterial genetic and metabolize information within urogenital cancer patients. 日本癌学会学術総会抄録集(Web). 2023. 82nd
SASSI Nesrine, 河嶋厚成, 山本顕生, 木村友則, 三田真史, 植村俊彦, 山道岳, 冨山栄輔, 石津谷祐, 山本致之, et al. Development of blood based diagnostic biomarker of urothelial carcinoma using a chiral amino acid: D-Alanine. 日本癌学会学術総会抄録集(Web). 2023. 82nd
河嶋厚成, 山本顕生, NESRINE Sassi, 木村友則, 三田真史, 植村俊彦, 山道岳, 冨山栄輔, 石津谷祐, 山本致之, et al. Development of blood based diagnostic markers of urothelial carcinoma using chiral amino acids. 日本泌尿器科学会総会(Web). 2023. 110th
加藤大悟, 森下康一, 冨山栄輔, 植村俊彦, 山本顕生, 奥田洋平, 藤田和利, 石津谷祐, 山本致之, 波多野浩士, et al. Fucosylated haptoglobin as a predictive biomarker following immune checkpoint inhibitors in advanced renal cell carcinoma. 日本泌尿器科学会総会(Web). 2023. 110th

ｍore...

Education (2)：

2009 - 2012 Osaka University Graduate School of Medicine Division of Surgical Medicine
1997 - 2003 Osaka University Faculty of Medicine Medical School

Professional career (1)：

医学博士 (大阪大学)

Work history (11)：

2022/04 - 現在大阪大学大学院医学系研究科泌尿器科講師
2019/04 - 2022/03 Osaka University Graduate School of Medicine
2017/03 - 2019/03 大阪国際がんセンター泌尿器科医長
2016/04 - 2017/03 大阪府立成人病センター泌尿器科医長
2015/04 - 2016/03 大阪府立成人病センター泌尿器科診療主任

Show all

Awards (5)：

2023/11 - 第37回日本泌尿器内視鏡・ロボティクス学会総会ビデオ部門総会賞
2021/06 - 大阪大学泌尿器科同窓会優秀論文賞
2017/06 - 大阪大学泌尿器科同窓会優秀論文賞
2014/02 - Johns Hopkins Prostate Research Day Poster Award
2012/02 - 第21回泌尿器分子・細胞研究会研究奨励賞

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page